Company Description
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases.
The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer.
Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 9, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 202 |
| CEO | Brian Thomas |
Contact Details
Address: 5959 Horton Street, 7th Floor Emeryville, California 94608 United States | |
| Phone | 510 871 4880 |
| Website | metagenomi.co |
Stock Details
| Ticker Symbol | MGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001785279 |
| CUSIP Number | 59102M104 |
| ISIN Number | US59102M1045 |
| Employer ID | 81-3909017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, Chief Executive Officer and Chairman of the Board |
| Dr. Jian Irish M.B.A., Ph.D. | President, Chief Operating Officer and Director |
| Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Dr. Joseph Knowles M.D. | Co-Founder and Member of Scientific Advisory Board |
| Matthew L. Wein J.D. | Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer |
| Dr. Alan Brooks Ph.D. | Head of Preclinical |
| Dr. Christopher Brown | Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | EFFECT | Notice of Effectiveness |
| Mar 21, 2025 | UPLOAD | Filing |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 17, 2025 | S-3 | Registration statement under Securities Act of 1933 |